Flaviviruses comprise a number of arthropod-borne infections, most of which are prevalent in tropical and subtropical regions around the globe [
1,
2,
3,
4]. Prominent members of the
Flavivirus genus include yellow fever (YFV), tick-borne encephalitis (TBEV), Japanese encephalitis (JEV), Zika (ZIKV), West Nile (WNV), and dengue (DENV) viruses [
5,
6]. DENV, transmitted by
Aedes spp. female mosquitoes (
A. albopictus and
A. aegypti), is estimated to infect approximately 400 million people per year, with some cases progressing to hemorrhagic dengue fever, leading to over 20,000 deaths worldwide every year [
3]. Whereas vaccines are available and effective against YFV, a broadly effective vaccine against all four subtypes of DENV (DENV-1 to DENV-4), or against ZIKV, remains elusive [
7,
8]. ZIKV, transmitted by the same mosquitoes, is also a global concern due, among other factors, to the continued expansion of these mosquito vectors. Approaches to deal with DENV and ZIKV infections focus mainly on relieving and managing the symptoms. Appropriate medical care of patients progressing to severe dengue can reduce the mortality rate from approximately 20% to 1% [
3]. However, this approach alone is insufficient, as medical care may not be affordable or available to vulnerable socio-economic groups in developing countries where flavivirus infections are most prevalent. Therefore, reducing the number of infections is also imperative. Moreover, as highlighted by the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic, rapid outbreaks can locally saturate medical care units, even in developed countries, by overwhelming the national healthcare system’s capacity. Further research of preventive or therapeutic strategies is critical, as their immediate availability could mitigate limited medical resources. In addition to accelerated spread, ZIKV poses risks not associated with DENV. Complications such as microcephaly and other neurological conditions arising from ZIKV infection may occur and add to a total mortality rate near 8%, as demonstrated in Brazil [
9]. Both DENV and ZIKV cases have been rising in recent years, not only in at-risk developing countries, but also in developed nations, since outbreaks associated with travel are now documented in Europe and North America [
3,
10,
11,
12]. Two causal factors, operating concurrently, increase the spread of flavivirus infection: (i) globalization of travel and trade, which escalates virus circulation by exposing naive populations to these infectious agents of foreign origin, plus (ii) the expansion of mosquito habitat due to climate change, urbanization, and other factors that help to establish reservoir vector populations in regions that were previously inhospitable to these arthropods [
13,
14,
15,
16,
17]. These changes in flaviviruses distribution and vector routes support predictions of further expansion worldwide. Thus, effective and readily available treatments and/or prophylactic measures have become a top priority of governments worldwide, with preventative actions being the best approach to deal with the devastating effects of major epidemics on affected populations and their countries’ economies.